TWST
Twist Bioscience Corporation · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.6% · net new positions -5.6% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 4.77K | $725,583 | n/a | n/a |
| Q2 2026 | 113 | +8 | 54.74M | $5.63B | +14 | −6 |
| Q1 2026 | 108 | +15 | 51.20M | $2.43B | +20 | −5 |
| Q4 2025 | 92 | -2 | 51.46M | $1.63B | +1 | −3 |
| Q3 2025 | 18 | 0 | 32.97M | $927.70M | +1 | −2 |
| Q2 2025 | 16 | -3 | 28.73M | $1.06B | n/a | −3 |
| Q1 2025 | 16 | +1 | 15.75M | $618.44M | +2 | −1 |
| Q4 2024 | 15 | 0 | 15.20M | $706.21M | n/a | n/a |
| Q3 2024 | 14 | +1 | 11.38M | $514.14M | +2 | −1 |
| Q2 2024 | 13 | n/a | 12.61M | $621.59M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 6.73M | +5.1% | $189.29M | 1.1% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 6.18M | -1.6% | $173.86M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 3 | The Vanguard Group ✦ (passive) | 5.77M | -1.1% | $162.32M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (passive) | 3.09M | +23.5% | $86.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | JPMorgan Chase ✦ | 2.04M | n/a | $57.31M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 6 | Millennium Management ✦ | 1.79M | +151.6% | $50.48M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.63M | n/a | $45.78M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | Morgan Stanley ✦ | 1.49M | n/a | $41.99M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Geode Capital Management ✦ (passive) | 1.45M | +1.7% | $40.76M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Baillie Gifford ✦ | 1.26M | +62.8% | $35.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 11 | Point72 Asset Management ✦ | 530.03K | -75.4% | $14.92M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 299.81K | -48.0% | $8.44M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 13 | Fidelity (FMR) ✦ | 219.53K | +1.1% | $6.18M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 207.91K | +40.0% | $5.85M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 15 | Citadel Advisors ✦ | 115.25K | -92.3% | $3.24M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 73.75K | -36.4% | $2.08M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 53.85K | +9.3% | $1.52M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 44.07K | New | $1.24M | 0.0% | New | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.24M | 0.0% |
Exited
| Norges Bank | $737,382 | was 0.0% |
| Renaissance Technologies | $507,702 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 279 holders, 76.80M shares, $3.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.46K sh · $384,823
Officer, Director · 45 sh · $9,336
Officer, Director · 146 sh · $30,199
Officer, Director · 297 sh · $61,116
Officer, Director · 290 sh · $59,392
Officer, Director · 432 sh · $87,958
Officer, Director · 1.02K sh · $205,763
Officer, Director · 1.84K sh · $368,806
Officer, Director · 481 sh · $96,804
Officer · 25.71K sh · $4.86M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology